Nucleic Acid Test (NAT) for Blood Transfusion – Explained

Nucleic Acid Test Latest News

• The Supreme Court has agreed to examine whether the Nucleic Acid Test (NAT) should be made compulsory in blood banks to ensure safer blood transfusion practices. 

Background of the Case

• The matter came before a Bench of the Chief Justice of India and two other judges after a petition was filed by an NGO seeking mandatory implementation of NAT across blood banks in India. 
• The petitioner argued that the right to safe blood transfusion forms part of the fundamental right to life under Article 21 of the Constitution. 
• The plea emphasised that NAT is a safer and more sensitive testing mechanism compared to existing screening methods and is necessary to prevent transfusion-transmitted infections.
• The Court has asked the petitioner to submit additional data on cost-effectiveness, State-level implementation, and feasibility before taking a final view. 

‹ ›

What is the Nucleic Acid Test (NAT)

• Nucleic Acid Test (NAT) is a highly sensitive molecular diagnostic technique that detects the genetic material (DNA or RNA) of viruses in donated blood. 
• It is capable of identifying infections such as Human Immunodeficiency Virus (HIV), Hepatitis B, and Hepatitis C.
• Unlike traditional serological tests, NAT reduces the “window period”, the time between infection and detectability, thereby enhancing blood safety.
• Currently, many blood banks in India primarily use Enzyme-Linked Immunosorbent Assay (ELISA) tests, which are less expensive but comparatively less sensitive during early infection stages.

Constitutional Dimension and Right to Life

• The petitioner has argued that access to safe and infection-free blood is an integral component of the right to life under Article 21. 
• The Supreme Court has previously interpreted Article 21 expansively to include the right to health, medical care, and dignity. 
• In this context, ensuring safe blood transfusion aligns with the constitutional obligation of the State to protect public health.
• The Court’s decision to examine the issue indicates recognition of the broader public health and human rights implications.

Cost and Feasibility Concerns

• During the hearing, the Bench raised questions regarding the financial feasibility of making NAT mandatory across all States. 
• The Court asked whether economically weaker States, already struggling with budgetary constraints, would be able to afford NAT in government blood banks and hospitals. 
• While the petitioner argued that the costs of NAT are comparatively low, the Court highlighted that additional financial burdens could affect States with limited fiscal capacity.
• The Bench has directed the petitioner to file an affidavit detailing:
  • Whether State hospitals currently use NAT
  • In how many hospitals is it implemented
  • The States where it is operational 
• This indicates that the Court is adopting a data-driven approach before considering mandatory nationwide implementation.

Public Health Context and Recent Incidents

• The issue has gained urgency due to reported cases of children contracting HIV allegedly due to contaminated blood transfusions.
• The petition referred to cases involving Thalassemia patients, who require frequent blood transfusions and are particularly vulnerable to infected blood. 
• Thalassemia is an inherited blood disorder in which the body cannot produce adequate haemoglobin. India has a high burden of Thalassemia patients, increasing the demand for safe and regular blood transfusions. 
• The case assumes greater significance against the backdrop of reported incidents in Madhya Pradesh and Jharkhand, where children were found HIV-positive following allegedly contaminated transfusions. 
• Such incidents have been described as “preventable tragedies” in the petition. 
• These events have reignited debate over the adequacy of existing blood screening mechanisms.

Policy and Regulatory Framework

• Blood safety in India is regulated under the Drugs and Cosmetics Act, 1940, and supervised by the National Blood Transfusion Council (NBTC) and State Blood Transfusion Councils.
• Currently, mandatory screening includes tests for HIV, Hepatitis B, Hepatitis C, malaria, and syphilis using serological methods. NAT is not uniformly mandated across all blood banks.
• Introducing compulsory NAT would require:
  • Infrastructure upgrades
  • Skilled laboratory personnel
  • Increased financial allocation
  • Standardisation across public and private sectors
• The decision, therefore, has implications for both health governance and fiscal policy.

Source: TH